Best of SABCS® - On Demand 2024
-
Register
- Member - $1
- Encore - $1
Intended Audience
This official Best of SABCS program is directed to practicing oncologists (medical, surgical, radiation), community physicians, medical residents and fellows training in oncology, as well as other pertinent healthcare professionals involved in oncology medicine.
Learning Objectives
After completion of this program, attendees should be able to:
· APPLY evidence-based strategies for preventing, detecting, and diagnosing breast cancer in at-risk patients.
· CONDUCT biomarker and genetic testing in patients with breast cancer using evidence-based principles to identify actionable mutations and other tumor characteristics that influence treatment approaches.
· INCORPORATE new results from preclinical research and clinical trials in all aspects of breast cancer care presented during oral, poster and educational sessions at the annual San Antonio Breast Cancer Symposium into clinical practice.
· INTEGRATE new data from clinical trials of novel therapeutics in breast cancer into local treatment patterns to align current practices with evidence based approaches, overcome resistance mechanisms, and enhance patient outcomes.
· DESIGN treatment plans for patients with breast cancer using individualized treatment strategies based on breast cancer subtype, clinical characteristics, and patient preferences and goals to optimize therapy.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The UT Health Science Center San Antonio and Encore Medical Education. The UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The UT Health Science Center San Antonio designates this live activity for a maximum of 5.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Duration
Release: February 12, 2025
Expiration: November 1, 2025
Disclaimers
The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.
This material may not be published, broadcast, rewritten, or redistributed in any form without prior authorization from Encore Medical Education. Your use of this website constitutes acceptance of Encore Medical Education's Privacy Policy and Terms & Conditions.
Key:
Complete
Next
Failed
Available
Locked
Hope Rugo
Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, CA
Dr. Rugo has disclosed financial relationships with ineligible companies as she is the principal investigator for Astellas Pharma Inc, AstraZeneca, Daiichi Sankyo, Inc, F. Hoffmann-La Roche, AG/Genentech, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Lilly, Merck, Novartis Pharmaceuticals Corporation, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Sermonix Pharmaceuticals Inc., Taiho Oncology, Inc., and Veru Inc.; has received travel support from Merck, AstraZeneca, and Gilead; and is a consultant for PUMA, Mylan, Daiichi Sankyo, Inc, and NAPO.
Mili Arora
Associate Professor of Internal Medicine, Hematology and Oncology,
Associate Director, Fellowship ProgramUC Davis Comprehensive Cancer Center
Does not have a relevant financial relationship with commercial interests to disclose.
Helen Chew
Professor of Medicine
Vice Chief, Hematology and Oncology
Director, Clinical Breast Cancer Program
UCDavis Comprehensive Cancer Center
Does not have a relevant financial relationship with commercial interests to disclose.
Jo Chien
Professor of Medicine
Medical Director, Breast Medical Oncology
University of California at San Francisco
Helen Diller Family Comprehensive Cancer Center
Does not have a relevant financial relationship with commercial interests to disclose.
Rita Mukhtar
Associate Professor of Clinical Surgery, Division of Surgical Oncology,
University of California at San Francisco
Dr. Mukhtar has disclosed a financial relationship with ineligible companies as she has received research funding from GE Healthcare.
Mark Pegram
Susy Yuan-Huey Hung Professor ofOncology
Medical Director, Clinical andTranslational Research Unit
Associate Dean for ClinicalResearch Quality
Stanford University School of Medicine
Dr. Pegram has disclosed a financial relationship with an ineligible company as he has received research funding from Biotheranostics/Hologic and Roche/Genentech.
Rebecca Shatsky
Associate Professor of Medicine
Breast Medical Oncology Co-TeamLeader
Scientific Director Inflammatory
and Triple Negative Breast CancerProgram
UC San Diego Comprehensive BreastHealth Team
Does not have a relevant financial relationship with commercial interests to disclose.
Melinda Telli
Professor of Medicine
Division of Medical Oncology
Stanford University School of Medicine
Does not have a relevant financial relationship with commercial interests to disclose.
To Claim CME Credit
“Please allow 7 – 10 business days for an email correspondence from the UT Health San Antonio Office of CME with instructions to complete the evaluation and to claim your credit/receive your certificate. If you should have any questions, please reach out to cme@uthscsa.edu.”
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Encore Medical Education or any company that provided commercial support for this activity.
Disclosure to Learners:
As an ACCME-accredited CME provider, The UT Health Science Center San Antonio must ensure that its CME activities are independent of the control of commercial interests. All speakers and planning committee members for the UT Health Science Center San Antonio sponsored programs are expected to disclose (prior to the activity) all “relevant financial relationships” as financial relationships in any amount occurring within the past 24 months that create a conflict of interest. (“Relevant” financial interest or other relationships can include such things as grant or research support, employees, consultants, major stockholders, members of speaker bureau, etc.)
The UT Health Science Center San Antonio, Hope Rugo, MD, course director and content reviewer Letti Bresnahan for the activity, have reviewed all financial disclosure information for all speakers, facilitators, and planning committee members; and determined and resolved all conflicts of interests.